Shuganhuazhuo Formula

Phase 2

Shuganhuazhuo Formula is one of 6 therapeutic programs targeting HCC - Hepatocellular Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

HCC - Hepatocellular CarcinomaNot yet recruiting

HCC - Hepatocellular CarcinomaPhase 2

Not yet recruiting

Competition

Competitive Landscape

6 competitors in HCC - Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Lenvima

Eisai

Phase 3

2 2

Beyfortus

BeiGene

Phase 3

1 3

QL1706

Qilu Pharmaceutical Co., Ltd.

Phase 3

1 4

Immunotherapy

Bristol-Myers Squibb

Phase 2

1 5

Targeted Therapy

FFudan University

Phase 2

1 6

Shuganhuazhuo Formula

XXiang-Qian

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2032

Phase 2Not yet recruiting

HCC - Hepatocellular Carcinoma

NCT07691645

Clinical

Trials by Indication[1]

HCC - Hepatocellular Carcinoma1 trial

Shuganhuazhuo Formula (Chinese Herbal Medicine) in the Combined Treatment of Advanced Hepatocellular Carcinoma With Damp-Heat and Blood Stasis Syndrome: An Open-Label Randomized Controlled Trial

Not yet recruiting·XXiang-Qian·Phase 2·NCT07691645·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Shuganhuazhuo Formula. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Shuganhuazhuo Formula. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Xiang-Qian company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: XXiang-Qian

Shuganhuazhuo Formula

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2032

Trials by Indication[1]

HCC - Hepatocellular Carcinoma1 trial

References

Drug Info

Quick Facts

Related News